RxDoctor Payments Data

Matthew Williams, MD

Critical Care Medicine · Annandale, VANPI 1629084918

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $191,775 of the $235,053 with a category attached, or 81.6%. AstraZeneca accounts for 84.4% of it on its own, with 39 other manufacturers making up the rest. Among critical care medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$235,053in general payments, 2019–2025

Across 666 payments — averaging $352.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$198K
  • Genentech USA, Inc.$13K
  • Amgen$10K
  • Insmed, Inc.$6K
  • GSK$3K
  • Sanofi$747
  • plus $4K from 34 others

What the payments were for

  • Consulting fees$16,2337%
  • Speaking & faculty fees$191,77582%
  • Travel & lodging$11,5495%
  • Food & beverage$15,2626%
  • Education$2350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$235,053 in reported general payments places this provider in the 95th percentile of 174 critical care medicine providers in Virginia.

See all critical care medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$481,812
Medicare patients
680
Services billed
9,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate53$567,151
Trelegy ElliptaFluticasone/Umeclidin/Vilanter311$378,303
TezspireTezepelumab-Ekko56$241,752
Dupixent PenDupilumab62$239,324
Fasenra PenBenralizumab35$209,209
ArikayceAmikacin Liposomal/Neb.Accessr12$174,701
Spiriva RespimatTiotropium Bromide96$78,597
Breztri AerosphereBudesonide/Glycopyr/Formoterol60$75,215
Pirfenidone17$73,789
Breo ElliptaFluticasone/Vilanterol105$71,699
EliquisApixaban59$71,058
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr79$65,918
Advair HfaFluticasone Propion/Salmeterol83$54,784
XolairOmalizumab15$41,145
Qvar RedihalerBeclomethasone Dipropionate65$34,551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$464$662,257169 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$2,804$557,178576 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Pulmicort Flexhaler$198,289$346,192184 claims
Insmed, Inc.Arikayce$6,370$174,70112 claims
PfizerEliquis$12$71,05859 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$71$34,55165 claims
Johnson & JohnsonXarelto$157$30,30727 claims
MerckDulera$13$15,58439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 174 critical care medicine providers in Virginia.

Other critical care medicine in Annandale

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →